John F. Valliant
Net Worth
Last updated:
What is John F. Valliant net worth?
The estimated net worth of Dr. John F. Valliant is at least $4,136,219 as of 27 Apr 2022. He has earned $1,599,719 from insider trading and has received compensation worth at least $2,536,500 in Fusion Pharmaceuticals Inc..
What is the salary of John F. Valliant?
Dr. John F. Valliant salary is $845,500 per year as Founder, Chief Executive Officer & Director in Fusion Pharmaceuticals Inc..
How old is John F. Valliant?
Dr. John F. Valliant is 55 years old, born in 1970.
What stocks does John F. Valliant currently own?
As insider, Dr. John F. Valliant owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fusion Pharmaceuticals Inc. (FUSN) | Founder, Chief Executive Officer & Director | 318,147 | $0 | $0 |
What does Fusion Pharmaceuticals Inc. do?
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
John F. Valliant insider trading
Fusion Pharmaceuticals Inc.
Dr. John F. Valliant has made 45 insider trades in 2022, according to the Form 4 filled with the SEC. Most recently he sold 4,511 units of FUSN stock worth $27,201 on 27 Apr 2022.
The largest trade he's ever made was exercising 33,202 units of FUSN stock on 16 Feb 2022. As of 27 Apr 2022 he still owns at least 318,147 units of FUSN stock.
Fusion Pharmaceuticals key executives
Fusion Pharmaceuticals Inc. executives and other stock owners filed with the SEC:
- Dr. Eric Burak Ph.D. (60) Chief Technology Officer
- Dr. James J. O'Leary (60) Chief Medical Officer
- Dr. John F. Valliant (55) Founder, Chief Executive Officer & Director
- Mr. John J. Crowley CPA (51) Chief Financial Officer